- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00781456
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo For the Management of Menstrually-Related Migraine Headaches.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
La Mesa, California, Stany Zjednoczone, 91942
- Teva Investigational Site
-
San Diego, California, Stany Zjednoczone, 92108
- Duramed Investigational Site
-
San Diego, California, Stany Zjednoczone, 92123
- Teva Investigational Site
-
San Francisco, California, Stany Zjednoczone, 94109-4841
- Duramed Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Stany Zjednoczone, 20036
- Duramed Investigational Site
-
-
Florida
-
West Palm Beach, Florida, Stany Zjednoczone, 33409
- Duramed Investigational Site
-
-
Georgia
-
Savannah, Georgia, Stany Zjednoczone, 31406
- Teva Investigational Site
-
-
New Jersey
-
Edison, New Jersey, Stany Zjednoczone, 08817
- Duramed Investigational Site
-
-
New York
-
New York, New York, Stany Zjednoczone, 10022
- Duramed Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27103
- Teva Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, Stany Zjednoczone, 74105
- Teva Investigational Site
-
-
Oregon
-
Medford, Oregon, Stany Zjednoczone, 97504
- Teva Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19114
- Duramed Investigational Site
-
Uniontown, Pennsylvania, Stany Zjednoczone, 15401
- Teva Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, Stany Zjednoczone, 29201
- Teva Investigational Site
-
Hilton Head, South Carolina, Stany Zjednoczone, 29926
- Teva Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone, 38120
- Teva Investigational Site
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75234
- Duramed Investigational Site
-
Houston, Texas, Stany Zjednoczone, 77054
- Teva Investigational Site
-
San Antonio, Texas, Stany Zjednoczone, 78258
- Duramed Investigational Site
-
-
Virginia
-
Virginia Beach, Virginia, Stany Zjednoczone, 23454
- Duramed Investigational Site
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98105
- Duramed Investigational Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Premenopausal, non-pregnant, non-lactating
- History of migraine headaches without aura for at least 6 months
- History of migraine headaches associated with menstruation
- Others as directed by FDA-approved protocol
Exclusion Criteria:
- History of migraine headaches with aura or focal neurological symptoms
- Any contraindication to the use of oral contraceptives
- Others as dictated by FDA-approved protocol
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: 91-day Levonorgestrel Oral Contraceptive
Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
|
91-dniowa kuracja składająca się z 84 niebieskich tabletek złożonych zawierających 150 µg LNG/30 µg EE i 7 żółtych tabletek zawierających 10 µg EE.
Inne nazwy:
|
Komparator placebo: Placebo
Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
|
1 tablet daily to match experimental arm
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period
Ramy czasowe: Baseline (25-35 days before Day 1) and Days 1-91
|
The number of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) through the end of the 91-day treatment period compared with Baseline (the 25- to 35-day baseline qualification period).
Participants recorded the incidence, timing and intensity of migraines in a migraine diary during the prequalification period and throughout the 91-day treatment period.
|
Baseline (25-35 days before Day 1) and Days 1-91
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the First, Second and Third Months
Ramy czasowe: Baseline, Month1, Month 2 and Month 3
|
The percentage of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) compared to Baseline at each month of the treatment period.
|
Baseline, Month1, Month 2 and Month 3
|
Change From Baseline in Average Migraine Severity
Ramy czasowe: Baseline and Month 1, Month 2 and Month 3
|
Migraine severity was recorded by participants in the Baseline qualification diary and study migraine diary during the treatment period. Participants could report a severity of none (score = 0), mild (1), moderate (2), or severe (3). In general, if a headache was mild, daily activities could be resumed and little to no medication was taken. Moderate headaches required medication and effected daily activities. Severe headaches were debilitating and required medication. Average migraine severity is defined as the sum of the severity ratings divided by the total number of migraine episodes reported during the observation period (for example, Baseline, First Month, Second Month, Third Month, and 91-Day Treatment Period). A negative change from Baseline score indicates improvement in severity. |
Baseline and Month 1, Month 2 and Month 3
|
Percentage of Participants Who Required Rescue Medications During the Study Period
Ramy czasowe: Baseline, Month 1, Month 2 and Month 3
|
Participants recorded use of rescue medications for migraines in the migraine diary during the course of study treatment.
|
Baseline, Month 1, Month 2 and Month 3
|
Change From Baseline in Migraine Disability Assessment
Ramy czasowe: Baseline and Week 15
|
The migraine disability assessment (MIDAS) test is used to determine how severely migraines affect a patient's life. Participants were asked five questions about how often their headaches limited their ability to go to work or school, to do household work or to do family or leisure activities in the past 3 months. The MIDAS score equals the sum of the days answered for each question and ranges from 0 (no disability) to approximately 270 (severe disability; the upper bound is dependent on the number of days a participant would plan to work or participate in other activities). The MIDAS score is classified into four grades of severity:
|
Baseline and Week 15
|
Change From Baseline in Headache Impact Test
Ramy czasowe: Baseline and Week 15
|
The Headache Impact Test (HIT) is a tool used to measure the impact headaches have on patients' ability to function on the job, at school, at home and in social situations. HIT-6 consists of 6 questions each scored on a scale from Never (6 points) to Always (13 points). The total score ranges from 36 to 78 with higher scores indicating greater impact on life. There was an error in administration of the HIT-6 in this study. Question 6 was not administered, and question 3 from the MIDAS was included instead. Therefore, the total score of the HIT-6 could not be calculated. |
Baseline and Week 15
|
Number of Participants With Adverse Events (AEs)
Ramy czasowe: Up to 15 weeks
|
An AE is any untoward medical occurrence in a clinical investigation participant and which does not necessarily have to have a causal relationship with this treatment or clinical study. The following definitions were used to assess AE severity: Mild: Awareness of signs or symptoms, but they are easily tolerated; Moderate: Enough discomfort to cause interference with usual activity; Severe: Incapacitating, with inability to perform usual activity. Relationship to study drug was assessed as either: None: Causal relationship can be ruled out; Possibly: Causal relationship at least reasonably possible, i.e. relationship cannot be ruled out; Definitely: Causal relationship is certain. A serious adverse event (SAE) is one that met any one of the following criteria:
|
Up to 15 weeks
|
Mean Number of Days of Bleeding or Spotting
Ramy czasowe: 91-day treatment period
|
Bleeding and spotting were recorded by participants in the migraine diary during the 91-day treatment period.
|
91-day treatment period
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Ból
- Objawy neurologiczne
- Zaburzenia związane z bólem głowy, pierwotne
- Zaburzenia związane z bólem głowy
- Zaburzenia migreny
- Ból głowy
- Fizjologiczne skutki leków
- Środki antykoncepcyjne, hormonalne
- Środki kontroli reprodukcji
- Środki antykoncepcyjne, kobiety
- Środki antykoncepcyjne, doustne, syntetyczne
- Lewonorgestrel
- Środki antykoncepcyjne
- Środki antykoncepcyjne, doustne
Inne numery identyfikacyjne badania
- DR-105-201
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .